BioInvent International AB (BINV) - Net Assets
Based on the latest financial reports, BioInvent International AB (BINV) has net assets worth Skr810.74 Million SEK as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr916.67 Million) and total liabilities (Skr105.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr810.74 Million |
| % of Total Assets | 88.44% |
| Annual Growth Rate | 7.4% |
| 5-Year Change | 19.14% |
| 10-Year Change | 2907.45% |
| Growth Volatility | 157.68 |
BioInvent International AB - Net Assets Trend (2000–2024)
This chart illustrates how BioInvent International AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioInvent International AB (2000–2024)
The table below shows the annual net assets of BioInvent International AB from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr885.82 Million | -32.37% |
| 2023-12-31 | Skr1.31 Billion | -18.45% |
| 2022-12-31 | Skr1.61 Billion | +17.49% |
| 2021-12-31 | Skr1.37 Billion | +83.86% |
| 2020-12-31 | Skr743.50 Million | +338.81% |
| 2019-12-31 | Skr169.44 Million | +93.37% |
| 2018-12-31 | Skr87.62 Million | -32.72% |
| 2017-12-31 | Skr130.22 Million | -43.49% |
| 2016-12-31 | Skr230.44 Million | +682.36% |
| 2015-12-31 | Skr29.45 Million | -43.82% |
| 2014-12-31 | Skr52.43 Million | +6.98% |
| 2013-12-31 | Skr49.01 Million | +2.90% |
| 2012-12-31 | Skr47.62 Million | -65.48% |
| 2011-12-31 | Skr137.95 Million | +85.94% |
| 2010-12-31 | Skr74.19 Million | +33.36% |
| 2009-12-31 | Skr55.63 Million | -75.95% |
| 2008-12-31 | Skr231.30 Million | +8.02% |
| 2007-12-31 | Skr214.12 Million | +94.38% |
| 2006-12-31 | Skr110.15 Million | -49.70% |
| 2005-12-31 | Skr219.00 Million | +2.97% |
| 2004-12-31 | Skr212.68 Million | -30.26% |
| 2003-12-31 | Skr304.96 Million | -22.65% |
| 2002-12-31 | Skr394.25 Million | +1.50% |
| 2001-12-31 | Skr388.42 Million | +143.32% |
| 2000-12-31 | Skr159.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioInvent International AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 51812.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr13.16 Million | 1.49% |
| Other Comprehensive Income | Skr1.00K | 0.00% |
| Other Components | Skr3.76 Billion | 424.38% |
| Total Equity | Skr885.82 Million | 100.00% |
BioInvent International AB Competitors by Market Cap
The table below lists competitors of BioInvent International AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sinch AB (publ)
LSE:0RBI
|
$158.34 Million |
|
ECB Bancorp Inc.
NASDAQ:ECBK
|
$158.34 Million |
|
Gaon Group Ltd
TA:GAGR
|
$158.35 Million |
|
Fountaine Pajo
PA:ALFPC
|
$158.36 Million |
|
Silver Mountain Resources Inc
V:AGMR
|
$158.25 Million |
|
Chongkundang
KO:001630
|
$158.24 Million |
|
Sino-Ocean Group Holding Limited
F:3SD
|
$158.20 Million |
|
Isu Chemical Co Ltd
KO:005950
|
$158.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioInvent International AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,309,727,000 to 885,815,000, a change of -423,912,000 (-32.4%).
- Net loss of 429,375,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-429.38 Million | -48.47% |
| Other Changes | Skr5.46 Million | +0.62% |
| Total Change | Skr- | -32.37% |
Book Value vs Market Value Analysis
This analysis compares BioInvent International AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.66x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.09x to 1.66x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | Skr243.54 | Skr22.35 | x |
| 2003-12-31 | Skr184.95 | Skr22.35 | x |
| 2004-12-31 | Skr128.98 | Skr22.35 | x |
| 2005-12-31 | Skr132.37 | Skr22.35 | x |
| 2006-12-31 | Skr44.74 | Skr22.35 | x |
| 2007-12-31 | Skr80.15 | Skr22.35 | x |
| 2008-12-31 | Skr79.60 | Skr22.35 | x |
| 2009-12-31 | Skr19.15 | Skr22.35 | x |
| 2010-12-31 | Skr23.46 | Skr22.35 | x |
| 2011-12-31 | Skr41.16 | Skr22.35 | x |
| 2012-12-31 | Skr12.76 | Skr22.35 | x |
| 2013-12-31 | Skr12.86 | Skr22.35 | x |
| 2014-12-31 | Skr11.66 | Skr22.35 | x |
| 2015-12-31 | Skr5.06 | Skr22.35 | x |
| 2016-12-31 | Skr22.76 | Skr22.35 | x |
| 2017-12-31 | Skr10.47 | Skr22.35 | x |
| 2018-12-31 | Skr6.34 | Skr22.35 | x |
| 2019-12-31 | Skr9.18 | Skr22.35 | x |
| 2020-12-31 | Skr25.89 | Skr22.35 | x |
| 2021-12-31 | Skr25.24 | Skr22.35 | x |
| 2022-12-31 | Skr26.11 | Skr22.35 | x |
| 2023-12-31 | Skr19.91 | Skr22.35 | x |
| 2024-12-31 | Skr13.46 | Skr22.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioInvent International AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -48.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -960.87%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.12x
- Recent ROE (-48.47%) is above the historical average (-86.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 11.71% | 53.03% | 0.20x | 1.13x | Skr6.74 Million |
| 2003 | 29.40% | 134.39% | 0.19x | 1.13x | Skr59.16 Million |
| 2004 | -43.50% | -157.48% | 0.25x | 1.12x | Skr-113.78 Million |
| 2005 | -63.86% | -496.00% | 0.11x | 1.22x | Skr-161.76 Million |
| 2006 | -98.80% | -214.12% | 0.34x | 1.35x | Skr-119.85 Million |
| 2007 | -7.52% | -11.22% | 0.53x | 1.27x | Skr-37.50 Million |
| 2008 | 7.03% | 6.45% | 0.85x | 1.28x | Skr-6.88 Million |
| 2009 | -317.55% | -219.02% | 0.64x | 2.27x | Skr-182.22 Million |
| 2010 | -173.07% | -154.95% | 0.60x | 1.86x | Skr-135.82 Million |
| 2011 | -48.61% | -53.79% | 0.61x | 1.49x | Skr-80.85 Million |
| 2012 | -394.43% | -437.40% | 0.37x | 2.45x | Skr-192.61 Million |
| 2013 | -36.81% | -22.08% | 1.00x | 1.66x | Skr-22.94 Million |
| 2014 | -102.97% | -115.03% | 0.63x | 1.41x | Skr-59.23 Million |
| 2015 | -307.87% | -569.43% | 0.29x | 1.85x | Skr-93.63 Million |
| 2016 | -27.16% | -87.80% | 0.26x | 1.20x | Skr-85.63 Million |
| 2017 | -77.20% | -223.33% | 0.26x | 1.31x | Skr-113.55 Million |
| 2018 | -140.56% | -319.51% | 0.32x | 1.37x | Skr-131.93 Million |
| 2019 | -82.10% | -148.41% | 0.41x | 1.33x | Skr-156.06 Million |
| 2020 | -10.31% | -52.02% | 0.18x | 1.08x | Skr-151.02 Million |
| 2021 | -20.41% | -1439.13% | 0.01x | 1.06x | Skr-415.66 Million |
| 2022 | -2.12% | -10.45% | 0.19x | 1.07x | Skr-194.70 Million |
| 2023 | -25.22% | -462.22% | 0.05x | 1.07x | Skr-461.28 Million |
| 2024 | -48.47% | -960.87% | 0.05x | 1.12x | Skr-517.96 Million |
Industry Comparison
This section compares BioInvent International AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $198,247,216
- Average return on equity (ROE) among peers: -74.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioInvent International AB (BINV) | Skr810.74 Million | 11.71% | 0.13x | $158.27 Million |
| 2cureX AB (2CUREX) | $13.62 Million | -53.33% | 0.76x | $3.24 Million |
| Ascelia Pharma AB (publ) (ACE) | $307.83 Million | -40.90% | 0.08x | $44.65 Million |
| AcouSort AB (ACOU) | $33.02 Million | -37.49% | 0.11x | $7.06 Million |
| Active Biotech AB (ACTI) | $32.07 Million | -122.86% | 0.35x | $20.99 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $6.55 Million |
| AlzeCure Pharma (ALZCUR) | $60.48 Million | -92.65% | 0.17x | $17.50 Million |
| Annexin Pharmaceuticals AB (ANNX) | $11.49 Million | -247.14% | 0.40x | $11.28 Million |
| Alligator Bioscience AB (ATORX) | $258.50 Million | -81.44% | 0.20x | $20.92 Million |
| BioArctic AB (publ) (BIOA-B) | $1.05 Billion | 21.90% | 0.13x | $2.57 Billion |
About BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more